Tislelizumab Plus Chemotherapy as First-Line Treatment for Advanced Squamous NSCLC With Brain Metastases
Status:
Recruiting
Trial end date:
2023-06-30
Target enrollment:
Participant gender:
Summary
This study is a prospective, single-arm, phase II clinical study to evaluate the efficacy and
safety of Tislelizumab Plus Chemotherapy in patients with squamous NSCLC with brain
metastases who had not previously received systemic therapy.